ADCYAP1R1
-
Official Full Name
adenylate cyclase activating polypeptide 1 (pituitary) receptor type I
-
Overview
This gene encodes type I adenylate cyclase activating polypeptide receptor, which is a membrane-associated protein and shares significant homology with members of the secretin receptor family. This receptor mediates diverse biological actions of adenylate cyclase activating polypeptide 1 and is positively coupled to adenylate cyclase. Multiple alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Dec 2010] -
Synonyms
ADCYAP1R1; adenylate cyclase activating polypeptide 1 (pituitary) receptor type I; PAC1; PAC1R; PACAPR; PACAPRI; pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP-R1; PACAP receptor 1; PACAP type I receptor; pituitary adenylate cyclase activating polypeptide 1 receptor type I Hiphop;
- Recombinant Proteins
- Cell & Tissue Lysates
- Antibody
- Protein Pre-coupled Magnetic Beads
- Assay Kits
- Bos taurus (Bovine)
- Chicken
- Homo sapiens (Human)
- Human
- Mus musculus (Mouse)
- Rat
- Rattus norvegicus (Rat)
- E.coli expression system
- HEK293
- Human Cell
- Mammalian Cell
- Wheat Germ
- Fc
- GST
- His
- His (Fc)
- Avi
- N/A
- Involved Pathway
- Protein Function
- Interacting Protein
- ADCYAP1R1 Related Articles
- ADCYAP1R1 Related Gene Family
- ADCYAP1R1 Related Research Area
ADCYAP1R1 involved in several pathways and played different roles in them. We selected most pathways ADCYAP1R1 participated on our site, such as Activation of TRKA receptors, Circadian entrainment, Class B/2 (Secretin family receptors), which may be useful for your reference. Also, other proteins which involved in the same pathway with ADCYAP1R1 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| Activation of TRKA receptors | NTF7;ADORA2A;ADCYAP1R1;ADCYAP1 |
| Circadian entrainment | PLCB1;ADCYAP1R1;GRIA2;GRIN2B;PRKCB;PLCB3;CACNA1G;CAMK2G;GNB1 |
| Class B/2 (Secretin family receptors) | PTHRP2;EMR4;SETD6;EMR1;CALCB;EMR3;CALCA;CRHR2;GNB3A |
| G alpha (s) signalling events | PTH;ADCYAP1;RLN3;GCGA;TAAR1;CRHR1;ADORA2B;ADM2;SCT |
| GPCR downstream signaling | PTH;LPAR2A;GPR132;AKAP13;DGKA;PIK3R6;ARHGAP4A;ARHGEF9;ECT2 |
| GPCR ligand binding | LPAR2B;CALCRL;AGTR2;HCRT;ADCYAP1R1;OXGR1;ANXA1;GPR77;CALCB |
| GPCRs, Class B Secretin-like | LPHN1;EMR2;CRHR2;CD97;ADCYAP1R1;CRHR1;CALCRL;ELTD1;EMR1 |
ADCYAP1R1 has several biochemical functions, for example, ADP-ribosylation factor binding, adenylate cyclase binding, neuropeptide binding. Some of the functions are cooperated with other proteins, some of the functions could acted by ADCYAP1R1 itself. We selected most functions ADCYAP1R1 had, and list some proteins which have the same functions with ADCYAP1R1. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| ADP-ribosylation factor binding | RAB11FIP3;RAB11FIP4A;ADCYAP1R1;RAB11FIP4;GGA3;GRASP;ZFP652;GGA2;SORL1 |
| adenylate cyclase binding | ADCYAP1R1;AKAP12;CHRNA7;ADRB2;AKAP5;CALM3;AKAP6;CALM1;CALM2 |
| neuropeptide binding | NPBWR2;NPY8BR;MC4R;OPRD1;GPR1;OPRD1A;MRGPRX2;SSTR4;PTGDR2 |
| protein binding | BLOC1S1;TAF2;HTT;ZNF576;ITGA1;YBX1;FRAS1;ZFP2;TCF7L1A |
| receptor activity | GRIA3B;ITGB4;NLGN4A;OGFRL2;APLNR;GFRA4A;RRBP1B;GRIA3A;TNFRSF11A |
| vasoactive intestinal polypeptide receptor activity | ADCYAP1R1;ADCYAP1R1A;VIPR1B;VIPR1;GHRHRL;VIPR2 |
ADCYAP1R1 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with ADCYAP1R1 here. Most of them are supplied by our site. Hope this information will be useful for your research of ADCYAP1R1.
CALM1
- Q&As
- Reviews
Q&As (14)
Ask a questionADCYAP1R1 protein therapy is not currently approved by the FDA for the treatment of mental health disorders. It is still in the experimental stages of development and clinical trials.
Side effects of ADCYAP1R1 protein therapy may include injection site reactions, fatigue, and dizziness. However, side effects are generally mild and resolve quickly.
ADCYAP1R1 protein therapy may be particularly effective in treating mental health disorders in individuals who have not responded to or cannot tolerate standard treatments such as psychotherapy or medication. Additionally, it may be effective in individuals with PTSD or depression who have elevated levels of stress hormones. Further research is needed to identify specific patient populations who may benefit from this treatment.
One of the main challenges associated with the development and use of ADCYAP1R1 protein therapy is the need for further research to determine its therapeutic potential and safety. Additionally, there may be issues related to cost and access to this type of treatment.
ADCYAP1R1 protein therapy is administered through intravenous injection, nasal spray, or subcutaneous injection.
Currently, there are no alternative treatments that work similarly to ADCYAP1R1 protein therapy. However, there are other treatments such as medication, therapy, and lifestyle changes that have been shown to be effective in the treatment of mental health disorders.
ADCYAP1R1 protein therapy is not a cure for mental health disorders. It is a potential treatment option that may provide relief from symptoms and improve quality of life for individuals with certain conditions. Regular and ongoing treatment may be necessary for long-term management of mental health disorders.
The time it takes for ADCYAP1R1 protein therapy to start working can vary among individuals, and studies examining its efficacy are ongoing. However, some studies have shown that improvements in symptoms may be seen within the first weeks of treatment.
ADCYAP1R1 protein therapy has shown promising results in the treatment of generalized anxiety disorder. However, more research is needed to determine its effectiveness for other types of anxiety disorders, such as panic disorder or social anxiety disorder.
ADCYAP1R1 protein therapy has shown potential for treating mental health conditions such as anxiety, post-traumatic stress disorder (PTSD), and depression. It has also been studied for its potential use in the treatment of Parkinson's disease and chronic pain.
ADCYAP1R1 protein therapy works by targeting a specific receptor in the brain called the pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1R). This receptor is involved in many important brain processes, including stress response, mood regulation, and memory formation.
ADCYAP1R1 protein therapy is not currently a first-line treatment for anxiety disorders. It is considered a second-line or adjunct treatment option for patients who have not responded to or cannot tolerate standard treatments such as antidepressants or benzodiazepines.
The potential benefits of ADCYAP1R1 protein therapy include the reduction of anxiety symptoms, such as excessive worry, restlessness, and difficulty sleeping.
The side effects of ADCYAP1R1 protein therapy are not well-known because it is still in the experimental stages of development. However, potential side effects could include headache, fatigue, nausea, and allergic reactions.
Ask a Question for All ADCYAP1R1 Products
Required fields are marked with *
My Review for All ADCYAP1R1 Products
Required fields are marked with *
